Patient perspectives of lithium and quetiapine augmentation treatment in treatment‐resistant depression: a qualitative assessment
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background: Treatment-resistant depression (TRD) has a profound cost to patients and healthcare services worldwide. Pharmacological augmentation is one therapeutic option for TRD, with lithium and quetiapine currently recommended as first-line agents. Patient opinions about pharmacological augmentation may affect treatment outcomes, yet these have not been systematically explored. Aims: This study aimed to qualitatively assess patient experiences of lithium and quetiapine augmentation. Methods: Semi-structured interviews were conducted with 32 patients from the ongoing lithium versus quetiapine open-label trial comparing these augmentation agents in patients with TRD. Interviews were audio recorded, transcribed and a thematic analysis was used to assess patient opinions of each agent. Results: Four main themes were generated from the thematic analysis: ‘Initial concerns’, ‘Experience of side effects’, ‘Perception of treatment efficacy’ and ‘Positive perception of treatment monitoring’. Patient accounts indicated a predominantly positive experience of lithium and quetiapine augmentation. Greater apprehension about side effects was reported for lithium prior to treatment initiation, but greater experience of negative side effects was reported for quetiapine. Clinical monitoring was perceived positively. Conclusion: Patient accounts suggested treatment augmentation with lithium or quetiapine was acceptable and helpful for most patients. However, anticipation and experiences of adverse side effects may prevent some patients from benefitting from these treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combination antidepressants, switching antidepressant treatment, dose optimization and the use of a host of augmentation strategies (e.g., lithium, thyroid hormone) have mixed data supporting their usefulness 288 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [288]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Using thematic analysis in psychology
Braun, V., & Clarke, V. (2006) · Qualitative Research in Psychology · doi:10.1191/1478088706qp063oa · Cited by 194,414
Research Methods for Clinical and Health Psychology
Marks, D., & Yardley, L. (2004) · SAGE Publications Ltd eBooks · doi:10.4135/9781849209793 · Cited by 901
Oliver, D. G., Serovich, J. M., & Mason, T. L. (2005) · Social Forces · doi:10.1353/sof.2006.0023 · Cited by 897
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · cited 1×
“Therapeutic options for patients with TRD include increasing the dose of ongoing antidepressant treatment, switching to an alternative antidepressant, combining antidepressants or augmentation with another agent (Cleare et al., 2015).”
BackgroundSelf-citationQualitative methods in research on healthcare quality
Pope, C. (2002) · Quality and Safety in Health Care · doi:10.1136/qhc.11.2.148 · Cited by 602
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Qualitative research and evidence based medicine
Green, J., & Britten, N. (1998) · BMJ · doi:10.1136/bmj.316.7139.1230 · Cited by 491
Overgeneral autobiographical memory as a predictor of the course of depression: A meta-analysis
Sumner, J. A., Griffith, J. W., & Mineka, S. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.03.013 · Cited by 413
Avery, A., Anderson, C., Bond, C., Fortnum, H., Gifford, A., Hannaford, P., Hazell, L., Krska, J., Lee, A., McLernon, D., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15200 · Cited by 331
Sleep Disturbances in Depression
Murphy, M. J., & Peterson, M. J. (2015) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2014.11.009 · Cited by 318
Research works printed but not linked: 1
- QSR International Ltd, 2012, NVivo 10
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationStrawbridge, R., & Young, A. H. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-024-00325-y · Cited by 21
Self-citationLithium Augmentation in Treatment‐Resistant Depression: A Qualitative Review of the Literature
Acero-González, Á., Guzmán, Y., Proaños, N., Bustos, R., Aconcha, M., Guerrero, I., Martinez, L. A., Berk, M., & Dodd, S. (2025) · Pharmacotherapy · doi:10.1002/phar.70063 · Cited by 5
Quantitative evaluation of multiple treatment regimens for treatment-resistant depression
Feng, Y., Lv, Y., Yang, J., Xu, L., Chen, J., Huang, J., Ren, J., Zheng, Q., & Li, L. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf007 · Cited by 5
Strawbridge, R., Myrtle, S., Carmellini, P., Hampsey, E., Cousins, D. A., & Young, A. H. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251328282 · Cited by 3
Self-citation
Metadata
- Authors
- McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., Young, A. H., & Cleare, A. J.
- Affiliations
- King's College London (GB)
- Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
- Oxford Health NHS Foundation Trust (GB)
- Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-04-27
- Volume
- 36
- Issue
- 5
- Pages
- 557-565
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC9112618
- OpenAlex
- W4225005363
- Cited by
- 12
- References
- 39
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 1 · 2022: 2
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Health Technology Assessment Programme (14/222/02)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, drug augmentation, lithium, quetiapine, patient experience, adverse effects, treatment monitoring, treatment acceptability
- MeSH terms
- Quetiapine Fumarate, Antidepressive Agents, Depression, Drug Therapy, Combination, Humans, Lithium, Antipsychotic Agents, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient perspectives of lithium and quetiapine augmentation treatment in treatment‐resistant depression: a qualitative assessment. https://app.cochat.ai/papers/10.1177/02698811221089042
- The paper
- McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., Young, A. H., & Cleare, A. J. (2022). Patient perspectives of lithium and quetiapine augmentation treatment in treatment‐resistant depression: a qualitative assessment. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221089042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.